| Inbound Relationships |
Type |
Active |
Source |
Characteristic |
Refinability |
Group |
| svovlmedikament |
Is a |
False |
keratolytisk middel |
Inferred relationship |
Some |
|
| Depilatory |
Is a |
False |
keratolytisk middel |
Inferred relationship |
Some |
|
| middel mod skæl |
Is a |
False |
keratolytisk middel |
Inferred relationship |
Some |
|
| ureamiddel til topikal anvendelse |
Is a |
False |
keratolytisk middel |
Inferred relationship |
Some |
|
| Contact dermatitis caused by keratolytic (disorder) |
Causative agent |
False |
keratolytisk middel |
Inferred relationship |
Some |
|
| Contact dermatitis due to keratolytic agent |
Causative agent |
False |
keratolytisk middel |
Inferred relationship |
Some |
|
| keratolyticum |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
keratolytisk middel |
Inferred relationship |
Some |
|
| Keratolytic agent |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
keratolytisk middel |
Inferred relationship |
Some |
|
| antiseboroisk medikament |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
keratolytisk middel |
Inferred relationship |
Some |
|
| salicylsyre 1% + anthraquinonglycosider 0,5 % præparat til oral pensling |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
keratolytisk middel |
Inferred relationship |
Some |
|
| ureacremer og -lotioner |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
keratolytisk middel |
Inferred relationship |
Some |
|
| Urea 100 mg/g cutaneous cream |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
keratolytisk middel |
Inferred relationship |
Some |
|
| Product containing precisely lauromacrogol 30 milligram/1 gram and urea 50 milligram/1 gram conventional release cutaneous cream (clinical drug) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
keratolytisk middel |
Inferred relationship |
Some |
|
| Product containing precisely urea 100 milligram/1 gram conventional release cutaneous lotion (clinical drug) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
keratolytisk middel |
Inferred relationship |
Some |
|
| Lactic acid 50 mg/g and urea 100 mg/g cutaneous cream |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
keratolytisk middel |
Inferred relationship |
Some |
|
| dithranol + salicylsyre 0,25 %/1,6 % gel til anvendelse i hårbunden |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
keratolytisk middel |
Inferred relationship |
Some |
|
| Product containing precisely coal tar 10 milligram/1 gram and dithranol 1.1 milligram/1 gram and salicylic acid 16 milligram/1 gram conventional release cutaneous ointment (clinical drug) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
keratolytisk middel |
Inferred relationship |
Some |
|
| Salicylic acid [psoriasis] |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
keratolytisk middel |
Inferred relationship |
Some |
|
| Salicylic acid 2% ointment BP |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
keratolytisk middel |
Inferred relationship |
Some |
|
| Zinc+salicylic acid paste BP |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
keratolytisk middel |
Inferred relationship |
Some |
|
| zink + salicylsyre-pasta i halv styrke |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
keratolytisk middel |
Inferred relationship |
Some |
|
| Salicylic acid [acne] |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
keratolytisk middel |
Inferred relationship |
Some |
|
| Product containing precisely salicylic acid 20 milligram/1 gram conventional release cutaneous solution (clinical drug) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
keratolytisk middel |
Inferred relationship |
Some |
|
| Salicylic acid [callosity] |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
keratolytisk middel |
Inferred relationship |
Some |
|
| Salicylic acid 20% 7.5cmx4.5cm plaster |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
keratolytisk middel |
Inferred relationship |
Some |
|
| Salicylic acid 40% 7.5cmx4.5cm plaster |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
keratolytisk middel |
Inferred relationship |
Some |
|
| Salicylic acid collodion BP 12% |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
keratolytisk middel |
Inferred relationship |
Some |
|
| Lactic acid 250 mg/g and salicylic acid 250 mg/g cutaneous ointment |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
keratolytisk middel |
Inferred relationship |
Some |
|
| salicylsyre + borsyre i renset talcum 3 %/5 % pudder |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
keratolytisk middel |
Inferred relationship |
Some |
|
| salicylsyre 5 % + zinkoxid 20 % pudder |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
keratolytisk middel |
Inferred relationship |
Some |
|
| salicylsyre 60 % i hvid blød paraffin 40 % salve |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
keratolytisk middel |
Inferred relationship |
Some |
|
| salicylsyre 17 % væske |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
keratolytisk middel |
Inferred relationship |
Some |
|
| Product containing precisely salicylic acid 260 milligram/1 milliliter conventional release cutaneous solution (clinical drug) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
keratolytisk middel |
Inferred relationship |
Some |
|
| Salicylic acid 110 mg/g cutaneous gel |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
keratolytisk middel |
Inferred relationship |
Some |
|
| salicylsyre + mælkesyre 16,7 %/16,7 % præparat til pensling |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
keratolytisk middel |
Inferred relationship |
Some |
|
| Product containing precisely salicylic acid 500 milligram/1 gram conventional release cutaneous ointment (clinical drug) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
keratolytisk middel |
Inferred relationship |
Some |
|
| Product containing precisely Podophyllum resin 200 milligram/1 gram and salicylic acid 250 milligram/1 gram conventional release cutaneous ointment (clinical drug) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
keratolytisk middel |
Inferred relationship |
Some |
|
| Product containing precisely salicylic acid 30 milligram/1 milliliter and sulfur 50 milligram/1 milliliter conventional release cutaneous shampoo (clinical drug) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
keratolytisk middel |
Inferred relationship |
Some |
|
| Product containing precisely salicylic acid 20 milligram/1 milliliter conventional release cutaneous lotion (clinical drug) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
keratolytisk middel |
Inferred relationship |
Some |
|
| Salicylic acid [antifungal] |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
keratolytisk middel |
Inferred relationship |
Some |
|
| Heparinoid 2 mg/g and salicylic acid 20 mg/g transdermal cream |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
keratolytisk middel |
Inferred relationship |
Some |
|
| Product containing precisely heparinoid 2 milligram/1 gram and salicylic acid 20 milligram/1 gram conventional release cutaneous gel (clinical drug) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
keratolytisk middel |
Inferred relationship |
Some |
|
| Salicylic acid product |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
keratolytisk middel |
Inferred relationship |
Some |
|
| Product containing precisely urea 400 milligram/1 milliliter conventional release cutaneous cream (clinical drug) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
keratolytisk middel |
Inferred relationship |
Some |
|
| Urea 400 mg/mL cutaneous lotion |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
keratolytisk middel |
Inferred relationship |
Some |
|
| urea 40 % |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
keratolytisk middel |
Inferred relationship |
Some |
|
| urinstof, c-14 1 mic kapsel |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
keratolytisk middel |
Inferred relationship |
Some |
|
| urea 40 g |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
keratolytisk middel |
Inferred relationship |
Some |
|
| Salicylic acid 60 mg/g cutaneous gel |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
keratolytisk middel |
Inferred relationship |
Some |
|
| mælkesyre + salicylsyre 16,7 %wt/wt/16,7 %wt/wt |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
keratolytisk middel |
Inferred relationship |
Some |
|
| salicylsyre gel |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
keratolytisk middel |
Inferred relationship |
Some |
|
| forgiftning med keratolytisk middel |
Causative agent |
False |
keratolytisk middel |
Inferred relationship |
Some |
|
| carbamidpræparat til topikal anvendelse |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
keratolytisk middel |
Inferred relationship |
Some |
|
| Lactic acid 40 mg/g and salicylic acid 120 mg/g cutaneous gel |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
keratolytisk middel |
Inferred relationship |
Some |
|
| Coal tar+salicylic acid ointment BP |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
keratolytisk middel |
Inferred relationship |
Some |
|
| Sulfur+salicylic acid cream BP |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
keratolytisk middel |
Inferred relationship |
Some |
|
| Sulfur+salicylic acid ointment BPC |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
keratolytisk middel |
Inferred relationship |
Some |
|
| Product containing precisely benzoic acid 60 milligram/1 gram and salicylic acid 30 milligram/1 gram conventional release cutaneous cream (clinical drug) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
keratolytisk middel |
Inferred relationship |
Some |
|
| Product containing salicylic acid (medicinal product) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
keratolytisk middel |
Inferred relationship |
Some |
|
| salicylsyre 20 % 7,5 cm x 4,5 cm plaster |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
keratolytisk middel |
Inferred relationship |
Some |
|
| salicylsyre 40 % 7,5 cm x 4,5 cm plaster |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
keratolytisk middel |
Inferred relationship |
Some |
|
| Product containing coal tar and salicylic acid and sulfur (medicinal product) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
keratolytisk middel |
Inferred relationship |
Some |
|
| kultjære 12 % + svovl 4 % + salicylsyre 2 % salve |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
keratolytisk middel |
Inferred relationship |
Some |
|
| Betamethasone (as betamethasone dipropionate) 500 microgram/g and salicylic acid 30 mg/g cutaneous ointment |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
keratolytisk middel |
Inferred relationship |
Some |
|
| betamethason + salicylsyre 0,05/3 % til anvendelse i hårbunden |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
keratolytisk middel |
Inferred relationship |
Some |
|
| Product containing betamethasone and salicylic acid (medicinal product) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
keratolytisk middel |
Inferred relationship |
Some |
|
| Product containing benzoic acid and salicylic acid (medicinal product) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
keratolytisk middel |
Inferred relationship |
Some |
|
| Product containing salicylic acid and sulfur (medicinal product) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
keratolytisk middel |
Inferred relationship |
Some |
|
| Product containing salicylic acid and zinc oxide (medicinal product) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
keratolytisk middel |
Inferred relationship |
Some |
|
| Product containing lauromacrogol and urea (medicinal product) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
keratolytisk middel |
Inferred relationship |
Some |
|
| Product containing dithranol and salicylic acid (medicinal product) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
keratolytisk middel |
Inferred relationship |
Some |
|
| Product containing desoximetasone and salicylic acid (medicinal product) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
keratolytisk middel |
Inferred relationship |
Some |
|
| Product containing camphor and salicylic acid (medicinal product) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
keratolytisk middel |
Inferred relationship |
Some |
|
FHIR